Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 22,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTIVE Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Effects of a Biofield Patch on Antioxidant Status and Cellular Energy

NCT07314359
View directory record Official record
Conditions
Antioxidant Status
Interventions
Active dermal patch, Placebo dermal patch
Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Recruiting Not applicable Interventional

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Cerritos, California • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Effects of Mindfulness on PTSD

NCT03484390
View directory record Official record
Conditions
Mindfulness, Stress Disorder, Posttraumatic
Interventions
Mindfulness-based stress reduction, Wellness Group
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008410
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers

NCT03843424
View directory record Official record
Conditions
Obesity, Childhood, Pediatric Obesity, Childhood Obesity, Adolescent Obesity, Overweight, Overweight and Obesity, Overweight or Obesity, Overweight Adolescents, Weight Gain, Overnutrition, Body Weight, Body Weight Changes, Nutrition Disorders
Interventions
eSOC program, FBT program
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 15 Years
Enrollment
1,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
7
States / cities
Alton, Illinois • Baton Rouge, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

NCT01013376
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
MC-1101, Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2009 · Synced Oct 28, 2026, 8:29 AM EDT
Recruiting Not applicable Interventional

Prehabilitation and Rehabilitation in PAD

NCT06566976
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Exercise Intervention, VAPAHCS Rehabilitation Core Components
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 28, 2026, 8:29 AM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)

NCT00929617
View directory record Official record
Conditions
Breast Cancer
Interventions
Experimental 1: exercise with 2 counseling types, Usual Care - written materials
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Champaign, Illinois • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 28, 2026, 8:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

NCT02440568
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Omacetaxine mepesuccinate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

NCT04283097
View directory record Official record
Conditions
Hematological Malignancies
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Sacramento, California • Plantation, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

NCT00799825
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
39
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 28, 2026, 8:29 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Reducing Opioid Use and Misuse After Wisdom Molar Extractions

NCT04414917
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Twin block, iPill dispenser
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Enrolling by invitation Phase 2 Interventional

The Unique and Combined Effects of Prenatal and Early Childhood Programming on Child Maltreatment: Examining Mechanisms of Change

NCT06732310
View directory record Official record
Conditions
Child Abuse, Intimate Partner Violence, Secondary Prevention, Parenting
Interventions
Pregnant Moms' Empowerment Program, Reminiscing and Emotion Training, Pregnancy - Active Control, Enhanced Case Management
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
3 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Notre Dame, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treatment for Patients With Chronic Post-Concussion Symptoms

NCT03759808
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion Post Syndrome
Interventions
Psychological Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Depressive Symptoms, Depression
Interventions
Cognitive Behavioral Therapy, Exercise, Group Discussions - Ongoing Support
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Insulin Regulation of Lipolysis and Lipolysis Proteins

NCT03866408
View directory record Official record
Conditions
Obesity
Interventions
Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Recruiting Phase 1 Interventional

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676
View directory record Official record
Conditions
High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions
CBX-250
Drug
Lead sponsor
Crossbow Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Duarte, California • Palo Alto, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Yoga for Aromatase Inhibitor-associated Joint Pain

NCT01951976
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaires, Yoga Classes
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 28, 2026, 8:29 AM EDT